Cite
HARVARD Citation
Beardslee, T. et al. (2019). Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor α therapy. Journal of oncology pharmacy practice. pp. 1275-1281. [Online].